Dishman Carbogen Amcis Limited — Important, 09-04-2025: Updates

Dishman Carbogen Amcis Limited's wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has successfully obtained a Drug Manufacturing License from the National Medical Product Administration for its facility in Shanghai, China. This approval is a significant milestone that enhances the subsidiary's operational capabilities and positions it for further growth in the pharmaceutical sector. The license will likely boost the subsidiary's competitive edge in the growing market for drug manufacturing in China, potentially attracting more clients and partnerships. Investors should watch closely for developments that could leverage this new capability into increased revenue and market opportunities.